A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder

Jazz Pharmaceuticals158 enrolled

Overview

The purpose of the study is to assess the safety and effectiveness of the experimental drug, a benzodiazepine drug, in long-term use and the effects on quality of life, social and occupational functioning, sleep, and daytime sedation in subjects with anxiety disorder.

This trial is a long-term, open label, safety and efficacy study of an experimental medication in adults with Generalized Anxiety Disorder (GAD). To enroll in this study, investigators and patients must have first participated in Jazz Pharmaceuticals, Inc. Protocol 04-001-01. The study is designed for four stages that should last a total of 37 weeks.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

158

Conditions

Anxiety Disorder

Interventions

a benzodiazepine drugDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Complete Study 04-001-01 * Able to take the medication for 9 months * Understand and sign the Informed Consent * Comply with all study-related procedures * Women of child bearing potential must have a confirmed negative urine pregnancy test * Lack of clinically significant abnormalities in health Exclusion Criteria: * Experienced any SAEs (serious adverse events) that were related or possibly related to study drug during participation in Study 04-001-01 * Early termination from study 04-001-01 * Any new condition that could interfere with the evaluation of the subject, interpretation of safety data, or compliance with the protocol requirements * Experiencing AEs (adverse events) such that in the opinion of the investigator, per protocol, study drug administration or safe participation in this study would be precluded. * Taken any disallowed medications noted in Study 04-001-01 between the completion of Study 04-001-01 and entry into this trial

Locations (13)

Florida Clinical Research Center

Bradenton, Florida, United States

Clinical Neuroscience Solutions, Inc.

Jacksonville, Florida, United States

Meridien Research

St. Petersburg, Florida, United States

Outcomes

Primary Outcomes

Assessment (over 37 additional weeks following the double-blind study) of the safety of the experimental drug in long-term use in subjects with Generalized Anxiety Disorder (GAD)

Secondary Outcomes

Evaluate the long-term efficacy of open-label study of the experimental drug in subjects with GAD

Assessment of the long-term effects on the quality of life, social and occupational functioning, sleep, and daytime sedation in subjects with GAD

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.